This is a serious kidney disease where the tiny filters in your kidneys get damaged. It's caused by inflammation and changes in the kidney's filtering units. It can happen on its own or because of other conditions like infections or autoimmune diseases. It often causes low levels of a protein called C3 in the blood.
Every report comes from a Lived member, sent anonymously.
Have you tried Fabhalta (Iptacopan) for Membranoproliferative Glomerulonephritis?
Membranoproliferative glomerulonephritis (MPGN) is a type of kidney inflammation that damages the glomeruli, the tiny filters that clean the blood and make urine. Immune proteins collect in the filter walls, the walls thicken and extra cells crowd in. Damaged filters can let blood and protein leak into the urine, and over time they can lose their ability to clear waste. That is why MPGN can lead to chronic kidney disease and, in many people, kidney failure. MPGN is a pattern a pathologist sees on a kidney biopsy rather than a single disease. Sometimes it is triggered by another illness, such as hepatitis C, lupus or an abnormal antibody made by blood cells. When no such cause is found it is called primary MPGN, which is rare and affects children as well as adults. Primary MPGN is now divided into immune-complex MPGN and C3 glomerulopathy. C3 glomerulopathy includes C3 glomerulonephritis and dense deposit disease, which was once called MPGN type II.
Every form of MPGN involves the immune system, and in particular complement, a group of blood proteins that normally helps fight infection. When complement is overactive or poorly controlled, its pieces lodge in the kidney filters and drive inflammation. In secondary MPGN, something else keeps the immune system switched on. Long-lasting infections such as hepatitis B, hepatitis C or a heart valve infection (endocarditis) can do this, as can autoimmune diseases such as lupus or Sjögren syndrome. A monoclonal protein, an abnormal antibody made by a single group of blood cells, is another important cause, and it can occur with or without a blood cancer such as lymphoma or leukemia. Specialists find one in roughly 20 to 40 percent of cases that would otherwise be called primary. In primary disease, many people have antibodies that interfere with the body's own complement controls, and about 1 in 5 carries a gene variant affecting those controls. These findings help explain the disease, but they usually do not decide treatment, and MPGN is not caused by anything a person did.
MPGN is often first suspected when routine urine tests show blood or protein, or when someone develops swelling, high blood pressure, or urine that looks dark or foamy. Some people have no symptoms at all. Others develop nephrotic syndrome, in which heavy protein loss causes marked swelling of the legs and around the eyes. Blood and urine tests measure how much protein the kidneys are leaking and how well they are filtering. Urine protein is often reported as a ratio to creatinine or as grams per day; healthy kidneys leak very little, and guidelines treat more than 1 gram a day as a sign of moderate to severe disease. Kidney filtering is reported as eGFR (estimated glomerular filtration rate), a blood-test estimate in which lower numbers mean weaker function. Low blood levels of the complement protein C3 are common and point toward this group of diseases. A kidney biopsy, in which a thin needle removes a small piece of kidney tissue, is needed to confirm MPGN. Special stains show whether the deposits contain antibodies along with C3 (immune-complex MPGN) or mostly C3 (C3 glomerulopathy). Because the same pattern can come from another disease, the workup also looks for hepatitis and other infections, autoimmune disease and monoclonal proteins. Complement and genetic tests may be added in primary disease.
Treatment depends on the cause, how much protein is leaking and how quickly kidney function is changing. When MPGN is secondary, treating the cause comes first, for example antiviral treatment for hepatitis C or treatment aimed at the blood cells that make a monoclonal protein. This can calm the kidney inflammation. Everyone with MPGN benefits from treatment that protects the kidneys. That includes tight blood pressure control, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (blood pressure medicines that also reduce protein leakage), and often an SGLT2 inhibitor, a medicine class that slows kidney decline. Limiting salt, not smoking and managing weight also help. Diuretics (water pills) can reduce swelling. For primary disease with significant protein loss or falling kidney function, two complement inhibitors are approved in the United States. Iptacopan (Fabhalta) is a twice-daily capsule for adults with C3 glomerulopathy. Pegcetacoplan (Empaveli) is infused under the skin twice a week for people 12 and older with C3 glomerulopathy or primary immune-complex MPGN. In trials both lowered urine protein substantially compared with placebo, and pegcetacoplan is approved to slow the loss of kidney function as well. Their long-term effect on avoiding kidney failure is still being studied. Because complement helps fight certain bacteria, these medicines raise the risk of serious infections such as meningitis. Vaccinations must be completed or updated at least 2 weeks before starting when possible, and they are available only through a special safety program. When complement inhibitors are not suitable or available, mycophenolate mofetil (CellCept), an immune-suppressing medicine, combined with steroids is an older option. It helps some people, but results have been mixed and relapse after stopping is common.
MPGN usually unfolds over years, and its course varies widely. Some people have mild urine changes and stable kidney function for a long time, while others lose function steadily. In primary MPGN, about half of people reach kidney failure within 10 years. People who keep leaking large amounts of protein tend to do worse, which is why lowering protein is a main treatment goal. Children tend to do better than adults. Day to day, living with MPGN usually means regular blood and urine tests, blood pressure checks at home and in clinic, and medicine adjustments. A salt-conscious diet matters, and some people need fluid or protein limits as kidney function falls. Long-term treatment with complement inhibitors or immune-suppressing medicine involves its own routines, including vaccines and attention to infection. If the kidneys fail, dialysis or a kidney transplant becomes necessary. MPGN can come back in a transplanted kidney, particularly C3 glomerulopathy, so transplant teams monitor closely, sometimes with planned biopsies, and complement inhibitors may be used if it returns. Because the disease is rare, care is usually led by a nephrologist (kidney specialist), ideally one experienced with glomerular disease.
See a clinician if a urine test shows blood or protein, or if you notice ongoing swelling, foamy or dark urine, or new high blood pressure readings. If you already have MPGN, contact your kidney team if swelling worsens, you pass much less urine than usual, or your urine turns cola colored. If you take iptacopan or pegcetacoplan, get emergency care right away for fever with a rash, a headache with a stiff neck, confusion, fast breathing, or fever with chills, and show your Patient Safety Card. These infections can become life threatening within hours.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Membranoproliferative Glomerulonephritis is like, what's helped you, or ask the community a question.